Featuring perspectives from Dr Hanny Al-Samkari, Dr Cindy Neunert and Prof Francesco Zaja, including the following topics:

• Introduction (0:00)
• Case: A woman in her early 30s with chronic relapsing immune thrombocytopenia (ITP) receives eltrombopag with ongoing stabilization of platelet counts — Neil Morganstein, MD (2:03)
• Case: A woman in her late 60s with a long history of ITP controlled by eltrombopag experiences acute exacerbations — Bhavana (Tina) Bhatnagar, DO (6:42)
• Clinical Manifestations and Initial Management of ITP — Dr Neunert (18:07)
• Case: A woman in her early 80s with metastatic adenocarcinoma of the lung who responded to carboplatin/pemetrexed/pembrolizumab presents with ITP after 14 months of maintenance pembrolizumab — Susmitha Apuri, MD (33:14)
• Incorporation of Thrombopoietin Receptor Agonists and Other Second-Line Therapies into ITP Management — Prof Zaja (40:19)
• Case: A woman in her late 60s with stress cardiomyopathy and corticosteroid-refractory ITP receives rituximab followed by eltrombopag — Eric Fox, DO (1:00:44)
• Current and Future Role of Novel Therapies in ITP — Dr Al-Samkari (1:03:47)

CME information and select publications

Featuring an interview with Dr Terence Friedlander, including the following topics:

• Final analysis of the Phase III, open-label, randomized POTOMAC trial (0:00)
• KEYNOTE-905 trial: Perioperative enfortumab vedotin with pembrolizumab for muscle-invasive bladder cancer (MIBC) (5:25)
• The neoadjuvant gemcitabine intravesical system TAR-200 for patients with MIBC: Primary analysis of the SunRISe-4 trial (14:07)
• Circulating tumor DNA-guided therapies for MIBC (18:41)

CME information and select publications

Featuring an interview with Dr Sagar Lonial, including the following topics:

• KLN-1010: A novel, in vivo gene therapy generating anti-BCMA chimeric antigen receptor T cells (0:00)
• Phase III DREAMM-7 and DREAMM-8 studies of belantamab mafodotin-based combination therapy for patients with relapsed/refractory (R/R) multiple myeloma (MM) (5:37)
• Effectiveness of ciltacabtagene autoleucel for patients with R/R MM (11:04)
• Low-dose tocilizumab for mitigation of the cytokine release syndrome associated with bispecific antibodies (16:04)
• Talquetamab with teclistamab for patients with R/R MM in Phase Ib of the RedirecTT-1 trial (19:24)

CME information and select publications

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics:

• Introduction (0:00)
• HER2-Targeted Approaches for Advanced Gastroesophageal Cancers — Dr Ajani (2:02)
• Faculty Panel Discussion: Cases and Questions from the Community (14:13)
• Targeting Claudin 18.2 in Advanced Gastroesophageal Cancers — Dr Strickler (37:29)
• Faculty Panel Discussion: Cases and Questions from the Community (49:21)
• Optimal Incorporation of Immunotherapeutic Strategies into Treatment for Patients with Metastatic Gastroesophageal Tumors — Dr Mehta (1:09:56)
• Faculty Panel Discussion: Cases and Questions from the Community (1:22:02)
• Other Novel Agents and Strategies Under Evaluation for Advanced Gastroesophageal Cancers — Dr Klempner (1:44:23)

CME information and select publications

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics:

• AKT inhibitors for PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (0:00)
• Radioligand-directed therapy for PSMA-positive metastatic hormone-sensitive prostate cancer (8:18)
• Radiation therapy in combination with enzalutamide for high-risk localized prostate cancer (13:14)

CME information and select publications

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics:

• Introduction (0:00)
• Biliary Tract Cancers — Dr Ellis (1:56)
• Gastroesophageal Cancers — Dr Wainberg (24:27)
• Colorectal Cancer — Prof Van Cutsem (59:13)

CME information and select publications

Featuring perspectives from Dr Angela DeMichele, Dr Komal Jhaveri, Dr Erica Mayer, Dr Hope S Rugo and Dr Seth Wander, including the following topics:

• Introduction (0:00)
• 1985 NCI Consensus Conference on Early Breast Cancer: Sir Richard Peto, FRS (2:01)
• Current Role of Genomic Assays in Treatment Decision-Making for Localized Hormone Receptor (HR)-Positive Breast Cancer — Dr DeMichele (5:13)
• Case: A premenopausal woman in her mid 40s with an ER-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC) after partial mastectomy/radiation therapy who enrolls in the prospective, observational FLEX study: MammaPrint® low risk — Laurie Matt-Amaral, MD, MPH (15:30)
• Case: A premenopausal woman in her mid 40s after modified radical mastectomy for T2N0 ER-positive, HER2-negative IDC with an Oncotype DX® Recurrence Score (RS®) of 19 — Swati Vishwanathan, MD
  Case: A woman in her mid 60s with locally advanced (19 cm) ER-positive, HER2-low (IHC 1+) Stage IIIB mucinous carcinoma breast cancer and an RS of 18 — Alan B Astrow, MD (22:40)
• Role of CDK4/6 Inhibitors and Other Novel Strategies in Therapy for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Jhaveri (30:18)
• Case: A woman in her mid 50s with ER-positive, HER2-negative Stage IIB, T2N1 IDC after neoadjuvant dose-dense AC-T, lumpectomy and adjuvant radiation therapy — Eleonora Teplinsky, MD (42:14)
• Case: A woman in her mid 60s with ER-positive, HER2-negative breast cancer with a surgically removed solitary lung metastasis after 4 years of adjuvant letrozole — Eric Fox, DO (46:32)
• Evolving Up-Front Treatment Paradigm for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Rugo (49:45)
• Case: A woman in her early 80s with Type 2 diabetes, well controlled hypertension and recurrent ER-positive, HER2-negative mBC after 4 years of adjuvant letrozole — Sunil Gandhi, MD (1:02:30)
• Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr Mayer (1:06:37)
• Case: A woman in her late 60s with ER-positive, HER2-low (IHC 1+), PIK3CA-mutant mBC with disease progression after 2 years of adjuvant letrozole — Laila Agrawal, MD (1:20:22)
• Case: A woman in her early 60s with ER-positive, HER2-low PIK3CA-mutant mBC and disease progression on first-line palbociclib/fulvestrant — Dr Teplinsky (1:26:36)
• Results from the Global Phase III lidERA Breast Cancer Trial of Giredestrant versus Standard Endocrine Therapy as Adjuvant Treatment for ER-Positive, HER2-Negative Localized Breast Cancer (1:31:48)
• Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (1:42:30)
• Case: A woman in her early 100s with locally advanced ER-positive, HER2-negative breast cancer with disease progression on letrozole, now with an ESR1 mutation — Dr Astrow (1:57:51)

CME information and select publications

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics:

• Case: A man in his early 60s with metastatic urothelial bladder cancer (mUBC) and medical history of tobacco use receives first-line enfortumab vedotin (EV) and pembrolizumab with excellent response after 3 cycles — Dr Fahey (0:00)
• Case: A woman in her early 80s with tumor mutational burden-high mUBC receives pembrolizumab with complete response and later discontinues after developing Grade 1 pneumonitis has no further evidence of disease — Dr Anari (9:19)
• Case: A man in his early 70s with mUBC who received single-agent EV develops neuropathy and hyperglycemia — Dr Anari (19:10)

CME information and select publications